Business
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
FDA approved AVLAYAH™ (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood-brain barrierAVLAYAH launched in U.S. with strong momentum, vibrant community engagement, and first patients treated in commercial setting in AprilBroad clinical pipeline progressing for lysosomal storage and neurodegenerative diseases, including first patient dosed with Oligonucleotide TransportVehicle™ (OTV)-enabled DNL628 (OTV:MAPT) tar
About this update from Denali Therapeutics Inc.
[{"type":"image","alt":"Denali Therapeutics Inc.","displaySize":"","headline":null,"caption":"Denali Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/649c66e2c9a2517794304178998a40c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cO_X7bXTP93LyjFvod8ZXA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY3/https://media.zenfs.com/en/globenewswire.com/649c66e2c9a2517794304178998a40c5","width":300,"height":48},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/cO_X7bXTP93LyjFvod8ZXA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY3/https://media.zenfs.com/en/globenewswire.com/649c66e2c9a2517794304178998a40c5","width":300,"height":48}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA approved AVLAYAH™ (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood-brain barrier","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"AVLAYAH launched in U.S. with strong momentum, vibrant community engagement, and first patients treated in commercial setting in April","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Broad clinical pipeline progressing for lysosomal storage and neurodegenerative diseases, including first patient dosed with Oligonucleotide TransportVehicle™ (OTV)-enabled DNL628 (OTV:MAPT) targeting tau for Alzheimer's disease","length":232,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancing DNL593 (PTV:PGRN) in Phase 1/2 study for GRN-related frontotemporal dementia after regaining full rights, with data expected by end of 2026","length":149,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":687,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business highlights, including the recent U.S. Food and Drug Administration (FDA) approval of AVLAYAH™ (tividenofusp alfa-eknm).","length":320,"tagName":"p"},{"type":"text","content":"“The FDA approval of AVLAYAH is a major milestone for Denali, for the Hunter syndrome community, and for the field of biotherapeutics enabled to cross the blood-brain barrier. We are thrilled by the strong en...